Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC). 6. Juni 2013 Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013. Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01 Abstract Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA. Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013. Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365… Weiterlesen Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO). Bergmann, L., Goebell, P., Kloß, S., Schirrmacher-Memel, S., Warnack, W., Kube, U., Scheffler, M., Doehn, C., Marschner, N., Rosé, C., Herrmann, E., 2014. Oncol Res… Weiterlesen